- Home
- CARM
as 05-20-2024 4:00pm EST
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 58.6M | IPO Year: | N/A |
| Target Price: | $9.20 | AVG Volume (30 days): | 175.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.34 - $9.77 | Next Earning Date: | 05-09-2024 |
| Revenue: | $15,073,000 | Revenue Growth: | 22.99% |
| Revenue Growth (this year): | 10.52% | Revenue Growth (next year): | 6.96% |
Share on Social Networks:
Latest Carisma Therapeutics Inc. News
CARM Breaking Stock News: Dive into CARM Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Simply Wall St.
6 days ago
Is There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?
Zacks
11 days ago
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
PR Newswire
11 days ago
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
PR Newswire
12 days ago
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
PR Newswire
14 days ago
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
Zacks
18 days ago
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
PR Newswire
18 days ago